PMID: 9182864Jan 1, 1997Paper

Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone

The Journal of Steroid Biochemistry and Molecular Biology
A HanukogluI Hanukoglu

Abstract

Type I pseudohypoaldosteronism (PHA) is a hereditary syndrome of salt wasting resulting from unresponsiveness to mineralocorticoids. PHA is manifested in two clinically and genetically distinct forms, affecting either only the kidney or multiple target organs of aldosterone. We examined the mineralocorticoid effect of carbenoxolone (CBX) in young PHA patients with either renal or multisystem resistance to aldosterone to find out whether CBX may help reduce the requirement for a high-salt diet. CBX did not show any significant salt-retaining effect in two patients with multiple PHA, and did not affect the renin-aldosterone system. In contrast, CBX significantly suppressed the renin-aldosterone system in a renal PHA patient for the whole duration of treatment, but without a long-term salt-retaining effect. On CBX treatment, urinary cortisone levels decreased and the cortisol:cortisone ratio increased, indicating that CBX inhibited 11beta-HSD activity that metabolizes cortisol to cortisone. The complete lack of effect of CBX on the renin-aldosterone system in multisystem PHA patients indicates that CBX does not exert an effect via mineralocorticoid (MR) or glucocorticoid receptors. Examination of the structure and expression of th...Continue Reading

References

Feb 1, 1979·The Journal of Clinical Endocrinology and Metabolism·S E OberfieldM I New
Aug 1, 1992·Kidney International·C P Bastl, J P Hayslett
Jan 1, 1991·The Journal of Steroid Biochemistry and Molecular Biology·D ArmaniniU Kuhnle
Mar 1, 1991·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·R J HoggJ C Frolich
Nov 1, 1988·Analytical Biochemistry·T A CiullaS L Hauser
Jan 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·G Miller, M Lipman
Sep 1, 1994·Current Opinion in Nephrology and Hypertension·B C RossierJ D Horisberger
Jul 28, 1994·The New England Journal of Medicine·P C White

❮ Previous
Next ❯

Citations

Sep 12, 2000·Current Hypertension Reports·D G Warnock
Apr 14, 2006·Journal of the American Society of Nephrology : JASN·David S GellerRichard P Lifton
Apr 10, 2004·Medical Law International·O Anson
May 31, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Wei-Ren LanHung-I Yeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.